Summit Therapeutics Inc. Common Stock
Here’s whether Summit Therapeutics Inc. Common Stock (SMMT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: 50-day MA is rising (+0.18% over 10 days); RSI 38 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); weak 1-year return of -25.1%; 3-month momentum negative (-6.0%); rising volume on a downtrend (distribution, 1.35x avg). Currently 52.3% off its 52-week high. Score: -3/7.
SMMT is trading below its 200-day MA ($18.48) — a key warning sign the longer-term trend is under pressure. An RSI of 37.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -25.1% compares to +24.4% for SPY (trailed the market by 49.5%). The current 52.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.